GENOVA Inc. (9341) AI Stock Analysis

• Market Cap: ¥10.18B
• Dividend Yield: 5.25%
• Average Volume (3M): 84.92K
• Price to Earnings (P/E): 10.9
• Beta (1Y): 1.08
• Revenue Growth: 0.09%
• EPS Growth: -48.79%
• Country: JP
• Employees: 352
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -5.67
• Shares Outstanding: 17,826,600
• 10 Day Avg. Volume: 127,530
• 30 Day Avg. Volume: 84,920
• PEG Ratio: -0.69
• Price to Book (P/B): 2.50
• Price to Sales (P/S): 1.75
• P/FCF Ratio: 16.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥756.00
• Price Target Upside: 32.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: ¥756.00 ▲(32.40% Upside)

GENOVA Inc. scores well due to its strong financial performance and attractive valuation. The company's robust revenue growth and solid balance sheet are significant strengths. However, mixed technical indicators suggest caution, as the stock is trading below key moving averages. The absence of earnings call data and corporate events limits additional insights.

GENOVA Inc. Business Overview & Revenue Model

Company Description

GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. It also provides Smart Clinic, an online medical treatment and consultation service, which offers medical treatment at home or work for users without going to a hospital. In addition, the company offers NOMOCa-Stand, a smart and simple automatic payment and reception machine; NOMOCa-Regi, a self-pay machine dedicated to the clinic; and CLINIC BOT, an AI Chatbot System. The company was founded in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

GENOVA Inc. generates revenue through multiple streams, primarily from the sale of its proprietary pharmaceuticals and biologics. The company partners with healthcare institutions and pharmaceutical distributors to market and distribute its products, which contributes significantly to its earnings. Additionally, GENOVA engages in strategic collaborations with other biotech firms and research institutions, allowing it to leverage shared resources and expertise, which often leads to co-development agreements and licensing deals. Furthermore, the company may receive funding through government grants and research grants aimed at supporting innovative medical research, enhancing its revenue potential.

GENOVA Inc. Financial Statement Overview

Summary

GENOVA Inc. demonstrates strong financial performance with robust revenue growth and high profitability margins. The balance sheet is solid with low leverage and high equity. Despite a slight decline in net profit margin and operating cash flow, the company's financial health remains strong, supported by effective cost management.

Income Statement

GENOVA Inc. has demonstrated strong revenue growth over the past years, with a notable increase from ¥3,768.67 million in 2021 to ¥10,006.10 million in 2025. The gross profit margin remains robust at approximately 73.7% in 2025, indicating effective cost management. However, the net profit margin has slightly decreased from 19.9% in 2024 to 14.1% in 2025, suggesting increased expenses or lower operational efficiency. Despite this, the company maintains a healthy EBIT margin of 20.2% and EBITDA margin of 21.0% in 2025, reflecting solid operational performance.

Balance Sheet

GENOVA Inc. exhibits a strong balance sheet with a high equity ratio of 82.1% in 2025, indicating financial stability and low leverage. The debt-to-equity ratio is minimal at 0.003, reflecting prudent debt management. Return on equity (ROE) remains impressive at 20.2% in 2025, showcasing effective utilization of shareholder funds. The company's substantial cash reserves further enhance its financial flexibility.

Cash Flow

The cash flow statement reveals a decline in operating cash flow from ¥1,822.12 million in 2024 to ¥1,194.85 million in 2025, impacting the operating cash flow to net income ratio. However, free cash flow remains positive at ¥1,058.97 million in 2025, indicating the company's ability to generate cash after capital expenditures. The free cash flow to net income ratio is strong, suggesting efficient cash management despite the decline in operating cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.32B	10.01B	8.68B	6.51B	4.80B	3.77B
Gross Profit	6.74B	7.38B	6.55B	4.79B	3.50B	2.63B
EBITDA	1.35B	2.10B	2.42B	1.77B	1.10B	821.56M
Net Income	931.13M	1.41B	1.73B	1.26B	686.27M	629.35M
Balance Sheet
Total Assets	7.58B	8.53B	8.20B	5.41B	2.82B	1.87B
Cash, Cash Equivalents and Short-Term Investments	5.18B	5.87B	5.97B	3.86B	1.65B	1.17B
Total Debt	8.33M	20.84M	377.78M	28.25M	163.50M	133.42M
Total Liabilities	1.16B	1.53B	2.16B	1.37B	1.33B	1.10B
Stockholders Equity	6.41B	7.00B	6.04B	4.04B	1.49B	768.34M
Cash Flow
Free Cash Flow	0.00	1.06B	1.77B	1.11B	508.47M	1.04B
Operating Cash Flow	0.00	1.19B	1.82B	1.20B	623.77M	1.06B
Investing Cash Flow	0.00	-275.93M	-94.24M	-113.45M	-179.06M	-68.18M
Financing Cash Flow	0.00	-1.01B	376.82M	1.13B	59.88M	-75.09M

GENOVA Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 571.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 571 is below the 20-day moving average (MA) of 648.10, below the 50-day MA of 664.22, and below the 200-day MA of 884.14, indicating a bearish trend. The MACD of -23.41 indicates Positive momentum. The RSI at 18.33 is Positive, neither overbought nor oversold. The STOCH value of 8.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.

GENOVA Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4320	73 Outperform	¥15.01B	14.26	―	2.48%	7.79%	38592.95%
9341	73 Outperform	¥10.18B	10.88	―	5.25%	0.09%	-48.79%
6095	72 Outperform	¥15.32B	10.15	―	0.65%	-17.86%	133.08%
3939	65 Neutral	¥22.00B	21.63	―	1.62%	13.39%	12.00%
3628	52 Neutral	¥7.57B	―	―	―	-2.60%	-103.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3902	43 Neutral	¥17.67B	4,465.71	―	1.19%	-0.58%	-260.22%

GENOVA Inc. Corporate Events

GENOVA Inc. Reports Q1 Loss but Forecasts Recovery

GENOVA Inc. reported a significant decline in its financial performance for the three months ended June 30, 2025, with net sales dropping by 26.9% and a net loss of ¥98 million compared to a profit in the previous year. Despite the current downturn, the company forecasts a recovery in net sales and profits for the fiscal year ending March 31, 2026, indicating a positive outlook for stakeholders.

The most recent analyst rating on (JP:9341) stock is a Buy with a Yen58.00 price target. To see the full list of analyst forecasts on GENOVA Inc. stock, see the JP:9341 Stock Forecast page.

GENOVA Inc. Revises 2026 Earnings Forecast Following Strategic Acquisition

GENOVA Inc. has revised its earnings forecast for the fiscal year 2026 due to a recent acquisition of a portion of ADI.G Co., Ltd.’s business. The revision reflects an increase in net sales but a decrease in profits, attributed to the conservative estimation of goodwill and intangible assets related to the acquisition. This strategic move is expected to impact GENOVA’s financial outlook and stakeholder expectations.

The most recent analyst rating on (JP:9341) stock is a Buy with a Yen58.00 price target. To see the full list of analyst forecasts on GENOVA Inc. stock, see the JP:9341 Stock Forecast page.

GENOVA Inc. Announces Executive Officer Appointments

GENOVA Inc. announced new appointments for its Directors and Executive Officers, effective June 25, 2025, following a resolution at an extraordinary Board of Directors meeting. These changes are expected to impact the company’s operations across various departments, potentially influencing its strategic direction and stakeholder relations.

The most recent analyst rating on (JP:9341) stock is a Buy with a Yen56.00 price target. To see the full list of analyst forecasts on GENOVA Inc. stock, see the JP:9341 Stock Forecast page.